Quantitative FDG-PET: a new biomarker in PMBCL.
Blood
; 126(8): 924-6, 2015 Aug 20.
Article
em En
| MEDLINE
| ID: mdl-26294712
In this issue of Blood, Ceriani et al introduce, in primary mediastinal B-cell lymphoma (PMBCL), a new prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET)/computed tomography (CT): the total lesion glycolysis (TLG), which is an index of the glucose uptake by the total tumor burden. This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective study designed to evaluate the role of PET in the treatment of PMBCL.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma Difuso de Grandes Células B
/
Neoplasias do Mediastino
/
Estadiamento de Neoplasias
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article